|Watch critically acclaimed PRC actress Zhao Wei endorsing Kino Biotech's beauty drinks.
Photos courtesy of Kino Biotech
STEP INTO the stores of Watsons, Guardian Pharmacy, Cold Storage and Giant, and one can't help but notice the ubiquitous Kinohimitsu brand.
Women, in particular, are familiar with Kinohimitsu beauty and collagen drink, the No. 1 selling brand in Malaysia and Singapore for three consecutive years
from 2008 to 2010.
The drinks, as well as health pads, healthcare tea, facial masks, cleanser, body cream and other skin care products, are manufactured by Kino Biotech, a healthcare and beauty company based in Singapore and listed in Taiwan.
Aside from Kinohimitsu, Kino Biotech’s Activa and Xpertise are brandnames which are gaining popularity in Singapore.
Kino Biotech hopes to replicate its success in Mynamar. Last Saturday, the company celebrated its appointment of Medi Myanmar Group to sell and distribute its Kinohimitsu, Activa and Xpertise brands.
About 400 guests attended the event at Traders Hotel in Yangon, including government officials from Myanmar and Singapore, and representatives from trade bodies, business organizations and non-governmental agencies.
Medi Myanmar Group is a leading a distributor of pharmaceutical and healthcare products, medical and fitness equipment, as well as consumer and lifestyle products.
It has a distribution network of more than 1,500 points of sales in Myanmar hypermarkets, supermarkets, pharmacies and grocery stores.
Among the products that will be available on the retail front are Kino Biotech’s award-winning detox juices, collagen drinks and health pads for men and women.
“We expect Myanmar’s healthcare and beauty market to take off with its political and economic liberalization,” said Kino Biotech’s executive chairman, Mr Ting Yen Hock.
The company estimates retail sales of over S$2 million in its first 18 months in Myanmar and projects annual growth of 30%. The first shipment of products went to Myanmar in December 2012.
Myanmar has a healthcare market estimated at around S$400 million and is expected to grow by 6.25 times in the next 10 years to reach S$2.5 billion.
For its established markets, Kino-Biotech is already exporting to China, Malaysia, Vietnam, Thailand and Indonesia. More than 80% of its revenue come from outside Singapore.
It is also in talks with distributors in the Middle East to penetrate markets such as Dubai, Saudi Arabia and Kuwait.